NCT07626788Not yet recruiting
Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis
Efficacy and Safety of Pentoxifylline as Add-On Therapy for Mild-to-Moderate Plaque Psoriasis: A Double-Blind Randomized Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis. Participants will be randomly assigned to receive either pentoxifylline or placebo twice daily for 12 weeks, while continuing their standard topical treatment. The study will compare improvement in psoriasis severity, itch, physician assessment, quality of life, and adverse events between the two groups. Participants will be followed for a total of 16 weeks.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 31 May 2026
- Start date
- 1 Nov 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- Wasuchon Chaichan
- Diseases
- Psoriasis
- NCT number
- NCT07626788
What you commit to
- Study type: Interventional
- Planned participants: 140
- From 1 Nov 2026 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of biologic agents within 12 weeks before enrollment.
- Psoriatic arthritis requiring systemic therapy.
Other illness
- Severe liver disease or severe kidney disease.
- History of significant bleeding disorder or current use of anticoagulant therapy that cannot be appropriately managed.
- Known hypersensitivity to pentoxifylline or related xanthine derivatives.
- Any serious medical condition or safety concern that, in the investigator's judgment, makes participation inappropriate.
Other
- Pregnant or breastfeeding.
- Refusal or inability to provide informed consent
Who the study is looking for
- Adults aged 18 to 65 years.
- Clinical diagnosis of mild-to-moderate plaque psoriasis, defined as Psoriasis Area and Severity Index (PASI) score 3 to 10 or body surface area (BSA) involvement 3% to 10%, as assessed by a physician.
- Receiving stable standard topical therapy for at least 2 weeks before enrollment.
- Able and willing to provide written informed consent.
- Willing to comply with the study protocol and scheduled follow-up visits.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Phayao Hospital Coordinator of this site? Confirm its status | Phayao | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.